Abcam, ab110124, Anti-cGKI antibody

Size: 50µg
Rabbit Polyclonal cGKI antibody. Suitable for WB, IHC-P and reacts with Human, Mouse, Rat samples. Cited in 5 publications. Immunogen corresponding to Synthetic Peptide within Human PRKG1 aa 650 to C-terminus conjugated to Keyhole Limpet Haemocyanin.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Rat, Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human PRKG1 aa 650 to C-terminus conjugated to Keyhole Limpet Haemocyanin. The exact immunogen used to generate this antibody is proprietary information.Q13976

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2Preservative: 0.09% Sodium azideConstituents: PBS, 50% Glycerol (glycerin, glycerine), Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CGKI also known as cyclic GMP-dependent protein kinase I or PKG I mechanically functions as an important player in the signaling pathways that depend on cyclic GMP (cGMP). cGKI is a serine/threonine protein kinase with a molecular mass of approximately 76 kilodaltons. It gets expressed in various tissues including vascular smooth muscle cells brain and platelets. The protein shows highest expression levels in tissues involved in smooth muscle regulation and neurological functions.
Biological function summary
The involvement of cGKI extends beyond basic signaling impacting diverse physiological processes. cGKI plays an important role in smooth muscle relaxation platelet function and nerve signaling. By phosphorylating various downstream targets cGKI affects muscle tone and neurotransmitter release. In the smooth muscle cGKI does not act independently but as part of a larger complex that modulates the cellular response to nitric oxide and natriuretic peptides.
Pathways
CGKI participates as an active component in the nitric oxide-cGMP signaling pathway. This pathway is significant in controlling vascular tone and neurotransmission. cGKI interacts with the proteins soluble guanylate cyclase and myosin light-chain phosphatase which together modulate blood vessel relaxation and contraction. Additionally cGKI plays a role in the cyclic nucleotide signaling pathways maintaining cardiovascular and neuronal health.
CGKI shows a connection to cardiovascular diseases and hypertension. Alterations in cGKI expression or function can lead to improper regulation of vascular tone contributing to elevated blood pressure. In the context of cardiovascular disorders cGKI interacts with proteins like PDE5A which also modulate cGMP levels in tissues. Understanding cGKI’s role in these diseases helps inform potential therapeutic targets for pharmacological intervention.